Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter studyopen access
- Authors
- Lee, Tae Yoon; Choi, Jung Sik; Oh, Hyoung-Chul; Song, Tae Jun; Do, Jae Hyuk; Cheon, Young Koog
- Issue Date
- Sep-2015
- Publisher
- KOREAN ASSOC INTERNAL MEDICINE
- Keywords
- Cholangiopancreatography; endoscopic retrograde; Pancreatitis; Udenafil; Aceclofenac
- Citation
- KOREAN JOURNAL OF INTERNAL MEDICINE, v.30, no.5, pp 602 - 609
- Pages
- 8
- Journal Title
- KOREAN JOURNAL OF INTERNAL MEDICINE
- Volume
- 30
- Number
- 5
- Start Page
- 602
- End Page
- 609
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/9145
- DOI
- 10.3904/kjim.2015.30.5.602
- ISSN
- 1226-3303
2005-6648
- Abstract
- Background/Aims: Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). Combination therapy with oral udenafil and aceclofenac may reduce the occurrence of post-ERCP pancreatitis by targeting different pathophysiological mechanisms. We investigated whether combining udenafil and aceclofenac reduced the rates of post-ERCP pancreatitis.
Methods: A prospective, randomized, double-blind, placebo-controlled, multi-center study was conducted in four academic medical centers. Between January 2012 and June 2013, a total of 216 patients who underwent ERCP were analyzed for the occurrence of post-ERCP pancreatitis. Patients were determined to be at high risk for pancreatitis based on validated patient and procedure-related risk factors.
Results: Demographic features, indications for ERCP, and therapeutic procedures were similar in each group. There were no significant differences in the rate (15.8% [17/107] vs. 16.5% [18/109], p = 0.901) and severity of post-ERCP pancreatitis between the udenafil/aceclofenac and placebo groups. One patient in each group developed severe pancreatitis. Multivariate analyses indicated that suspected dysfunction of the sphincter of Oddi and endoscopic papillary balloon dilation without sphincterotomy were associated with post-ERCP pancreatitis.
Conclusions: Combination therapy with udenafil and aceclofenac is not effective for the prevention of post-ERCP pancreatitis.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/9145)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.